Back to Search Start Over

Humoral signatures of MOG-antibody-associated disease track with age and disease activity.

Authors :
Spatola M
Chuquisana O
Jung W
Lopez JA
Wendel EM
Ramanathan S
Keller CW
Hahn T
Meinl E
Reindl M
Dale RC
Wiendl H
Lauffenburger DA
Rostásy K
Brilot F
Alter G
Lünemann JD
Source :
Cell reports. Medicine [Cell Rep Med] 2023 Feb 21; Vol. 4 (2), pp. 100913. Date of Electronic Publication: 2023 Jan 19.
Publication Year :
2023

Abstract

Myelin oligodendrocyte glycoprotein (MOG)-antibody (Ab)-associated disease (MOGAD) is an inflammatory demyelinating disease of the CNS. Although MOG is encephalitogenic in different mammalian species, the mechanisms by which human MOG-specific Abs contribute to MOGAD are poorly understood. Here, we use a systems-level approach combined with high-dimensional characterization of Ab-associated immune features to deeply profile humoral immune responses in 123 patients with MOGAD. We show that age is a major determinant for MOG-antibody-related immune signatures. Unsupervised clustering additionally identifies two dominant immunological endophenotypes of MOGAD. The pro-inflammatory endophenotype characterized by increased binding affinities for activating Fcγ receptors (FcγRs), capacity to activate innate immune cells, and decreased frequencies of galactosylated and sialylated immunoglobulin G (IgG) glycovariants is associated with clinically active disease. Our data support the concept that FcγR-mediated effector functions control the pathogenicity of MOG-specific IgG and suggest that FcγR-targeting therapies should be explored for their therapeutic potential in MOGAD.<br />Competing Interests: Declaration of interests The authors declare no competing interests.<br /> (Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
2666-3791
Volume :
4
Issue :
2
Database :
MEDLINE
Journal :
Cell reports. Medicine
Publication Type :
Academic Journal
Accession number :
36669487
Full Text :
https://doi.org/10.1016/j.xcrm.2022.100913